Pertuzumab prolongs survival in MBC, no adverse effect on QOL.

Zdroj: PharmacoEconomics & Outcomes News. 8/1/2013, Issue 684, p9-9. 1p.
Databáze: Academic Search Ultimate
Externí odkaz: